We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > VR475

News List

Phase 3 failure of asthma therapy sends Vectura's ailing shares falling pharmafile
November 28, 2018
Vectura has announced it is terminating development of its severe asthma therapy VR475, an inhaled formulation of the corticosteroid budesonide, after it failed in Phase 3 trials to demonstrate...
Vectura pulls the plug on experimental asthma therapy contractpharma
November 28, 2018
Vectura says it no longer plans to develop and partner experimental asthma therapy VR475, after it failed to hit Phase III targets.
Vectura takes £40 million hit as asthma drug fails trial pharmaphorum
November 28, 2018
Vectura has abandoned a late-stage drug in severe uncontrolled asthma after it failed a phase 3 trial, resulting in a decline in its already-depressed share price.